Neurotech International Ltd. (AU:NTI) has released an update.
Neurotech International Ltd reports promising results from its Phase II/III clinical trial for NTI164, a treatment for Autism Spectrum Disorder, showing significant improvements in severity of illness, adaptive behaviors, and socialization without serious side effects. The company highlights the absence of current FDA or TGA-approved treatments that address autism’s core symptoms, underscoring the potential of NTI164 to meet a substantial unmet market need. Additionally, a Phase I/II clinical trial shows safety and sustained clinical improvement over two years of treatment.
For further insights into AU:NTI stock, check out TipRanks’ Stock Analysis page.
